Global Cystic Fibrosis Therapeutics Market Overview
The cystic fibrosis therapeutics market accounted for US$ 5.3 billion in 2019 and is estimated to be US$ 25.6 billion by 2029 and is anticipated to register a CAGR of 17.2%
Cystic fibrosis is a hereditary disorder, which highly affects the lungs and other body parts such as liver, kidney, and pancreas. It is a mutation in an in the cystic fibrosis transmembrane conductance regulator (CFTR) gene a protein that regulates the movement of salts in and out of cells. However, mutation of this gene results to the absence of CFTR activity, which in turn alters the protein structure and results in loss of chloride. Patients undergo difficulty in breathing, fatty stool, mucus formation, and difficulty in the passageway of the pancreas, intestine, bile duct, & salivary gland. Cystic fibrosis is detected by the usage of a sweat test and genetic testing. Treatment of cystic fibrosis includes physical therapy that helps in the reduction of mucus formation and fights against infections of an organ. Additionally, the use of drugs such as Pulmozyme, Kalydeco, and others. The cystic fibrosis therapeutics market accounted for US$ 5.3 billion in 2019 and is estimated to be US$ 25.6 billion by 2029 and is anticipated to register a CAGR of 17.2%.
Impact of COVID-19 on the market
Biopharmaceutical firms are at the leading position of the human response to the coronavirus pandemic. A significant number of foremost biotech organizations are in the middle of a race to examine the Sars-Cov-2 genome and formulate a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a significant amount of funds are being put into the R&D. With the several candidates in the trial, the public and private sectors are expected to work in unison for the estimative period, until a vaccine is developed for Covid-19. This report will quantify the impact of this pandemic on the cystic fibrosis therapeutics market.
Global Cystic Fibrosis Therapeutics Market Dynamics
Growing prevalence of Cystic Fibrosis (CF)
According to the data published by the Cystic Fibrosis Foundation, the occurrence of these hereditary disorders is growing constantly. In 2015, in the U.S., there were 28,983 patients as compared to 26,366 patients in 2010. Swelling year-on-year growth in the number of patient’s additional results in the growing demand for efficient and effective CF therapeutics. Some of the commercially available approved drug class are Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, mucolytic drugs, bronchodilators drugs, anti-infective, anti-inflammatory drugs, antibiotics (oral, inhaled, or parental feeding formulae), and pancreatic enzyme supplements.
Growth in the number of initiatives concerning to development of NASH drugs
Favourable initiatives taken by regional and national nonprofit organizations is one of the key factors boosting the growth of the target market. These initiatives provide funding to CF patients. These organizations help in research & development activities of these therapeutics and improve the patient’s quality of life. For example, the North American Cystic Fibrosis Conference (NACFC) was formed in 1986 to offer a collaborative and educational forum to CF professionals to share improvements in R&D related to CF therapeutics.
Conversely, higher cost of treatment and low awareness in developing nations are anticipated to hamper the growth of the cystic fibrosis therapeutics market during the forecast period.
Global Cystic Fibrosis Therapeutics Market Segmentation
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
The cystic fibrosis therapeutics market is segmented based on the drug class, route of administration, and region.
On the basis of the drug class, the cystic fibrosis therapeutics market is segmented into pancreatic enzyme supplements, mucolytics, bronchodilators, and CFTR modulators. Based on the route of administration, the target market is classified into oral drugs and inhaled drugs.
Regional Insights:
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
In the region, the cystic fibrosis therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America estimated for the highest revenue share in 2019, owing to growing number of patients suffering from cystic fibrosis. Additionally, initiatives taken by CF Foundation and Cystic Fibrosis Canada are one of the vital reasons that can be estimated for its maximum share. Asia Pacific is projected to be the fastest growing segment with a profitable growth rate. Moreover, growing awareness about CF disorders & treatment options is anticipated to fuel this segment throughout the forecast period. Improving healthcare facilities and economic development in this region and are projected to propel the market growth during the forecast period. Increasing awareness amongst healthcare professionals & patient population concerning advanced therapeutics in the market & their benefits over the existing drug portfolio is one of the essential factors expected to drive the market in the upcoming years. Currently, the presence of CF-specific drugs is low. Nevertheless, growing approvals and product launches in this market are projected to impel growth.
|
Attribute |
Details |
|
The base year for estimation |
2019 |
|
Forecast period |
2019 – 2029 |
|
Market representation |
Revenue in USD Million & CAGR from 2019 – 2029 |
|
Market Segmentation |
By Drug Class - Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, and CFTR Modulators By Route of Administration – Oral Drugs and Inhaled Drugs |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the cystic fibrosis therapeutics market report based on drug class, route of administration, and region.
Cystic Fibrosis Therapeutics Market, By Drug Class:
- Pancreatic Enzyme Supplements
- Mucolytics, Bronchodilators
- CFTR Modulators
Cystic Fibrosis Therapeutics Market, By Route of Administration:
- Oral Drugs
- Inhaled Drugs
Cystic Fibrosis Therapeutics Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- U.S.
- Canada
- Middle East & Africa
Global Cystic Fibrosis Therapeutics Market Key Players
The key players operating in the cystic fibrosis therapeutics market include AbbVie Inc., Hoffmann-La Roche Ltd., Allergan, Gilead Sciences, Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Novartis AG, Alcresta Therapeutics Inc., AstraZeneca Plc., and Alaxia. The prominent players are constantly involved in the development of new or combination of products to treat cystic fibrosis. Investment in R&D is one of the planned measures to beat the competition. For instance, in February 2020, Allergan has entered into a definite agreement to sell Zenpep (pancrelipase), a therapy for exocrine pancreatic insufficiency due to cystic fibrosis (CF) and other conditions.
Global Cystic Fibrosis Therapeutics Market Company Profile
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Hoffmann-La Roche Ltd.
- Allergan
- Gilead Sciences, Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co. Inc.
- Novartis AG
- Alcresta Therapeutics Inc.
- AstraZeneca Plc.
- Alaxia
“*” marked represents similar segmentation in other categories in the respective section
Global Cystic Fibrosis Therapeutics Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Drug Classs
- Key Thickness Insights
- Secondary Data
- Major Secondary Drug Classs
- Secondary Drug Classs
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for Cystic Fibrosis Therapeutics Strategies
- Key Questions this Study will Answer
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Drug Class, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Pancreatic Enzyme
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Supplements
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Mucolytics
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Bronchodilators
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- CFTR Modulators
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Market Segmentation, By Route of Administration, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Oral drugs
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Inhaled drugs
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Global Market, By Region, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Drug Class, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Route of Administration, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Drug Class, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Route of Administration, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Drug Class, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Route of Administration, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Drug Class, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Route of Administration, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Drug Class, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Route of Administration, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
-
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Hoffmann-La Roche Ltd.
- Allergan
- Gilead Sciences, Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co. Inc.
- Novartis AG
- Alcresta Therapeutics Inc.
- AstraZeneca Plc.
- Alaxia
- AbbVie Inc.
-
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The global cystic fibrosis therapeutics market is segmented based on drug class, route of administration, and region.
Increase in prevalence of cystic fibrosis is likely to drive the growth of the global cystic fibrosis therapeutics market over the forecast period.
North America estimated for the highest revenue share in 2019, owing to the growing number of patients suffering from cystic fibrosis.
The prominent players are constantly involved in the development of new or combination of products to treat cystic fibrosis. Investment in R&D is one of the planned measures to beat the competition.